Emerging treatment modalities for systemic therapy in hepatocellular carcinoma

Biomarker Research

Wenjing Xu¹  Xuanlong Du¹  Hao Peng¹  Xin Qing¹  Jingjing Zong¹  Yewei Zhang¹ 

[1] Department of General Surgery, Zhongda Hospital, Medical School, Southeast University, 210009, Nanjing, China;

关键词: Hepatocellular carcinoma;    Targeted therapy;    Immunotherapy;    Tyrosine kinase inhibitors;    Immune checkpoint inhibitors;    Signalling pathway;   

DOI  :  10.1186/s40364-021-00319-3

来源: Springer

【 摘 要 】

Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with advanced HCC remains to be resolved. Fortunately, the past few years have shown the emergence of successful systemic therapies to treat HCC. At the molecular level, HCC is a heterogeneous disease, and current research on the molecular characteristics of HCC has revealed numerous therapeutic targets. Targeted agents based on signalling molecules have been successfully supported in clinical trials, and molecular targeted therapy has already become a milestone for disease management in patients with HCC. Immunotherapy, a viable approach for the treatment of HCC, recognizes the antigens expressed by the tumour and treats the tumour using the immune system of the host, making it both selective and specific. In addition, the pipeline for HCC is evolving towards combination therapies with promising clinical outcomes. More drugs designed to focus on specific pathways and immune checkpoints are being developed in the clinic. It has been demonstrated that some drugs can improve the prognosis of patients with HCC in first- or second-line settings, and these drugs have been approved by the Food and Drug Administration or are nearing approval. This review describes targeting pathways and systemic treatment strategies in HCC and summarizes effective targeted and immune-based drugs for patients with HCC and the problems encountered.

【 授权许可】

CC BY